



## **Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics**

September 30, 2021

CAMBRIDGE, Mass. and NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the presentation of pre-clinical data for three pipeline programs in oral and poster sessions at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.

Oral presentation information is as follows:

**Title:** BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat osimertinib-resistant NSCLC with or without brain metastases

**Session Title:** Plenary Session 2: New Drugs on the Horizon I

**Abstract Number:** 5208

**Presentation Date:** Friday, October 8, 11:05-11:20 AM ET

Poster presentation information is as follows:

**Title:** Pre-clinical evaluation of next-generation inhibitor targeting a wide spectrum of oncogenic BRAF dimers

**Poster Number:** P229

**Title:** Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers

**Poster Number:** P246

Full abstracts will be available on the meeting platform at the start of the meeting on Thursday, October 7, 2021 at 9:00 AM ET.

### **About Black Diamond Therapeutics, Inc.**

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's proprietary technology platform and drug discovery engine, the Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy that targets a specific family of mutations, termed a MasterKey therapy. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit [www.blackdiamondtherapeutics.com](http://www.blackdiamondtherapeutics.com).

### **Contacts:**

#### **For Investors:**

Natalie Wildenradt

[investors@bdtx.com](mailto:investors@bdtx.com)

#### **For Media:**

Kathy Vincent

(310) 403-8951

[media@bdtx.com](mailto:media@bdtx.com)